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Chronic Kidney Disease
for the PCP
Lilli Flink, MD
PGY-2
Department of Family & Community Medicine

• 90% of adults
with CKD are
unaware of their
condition
• 40% of adults
with severe CKD
are unaware of
their condition

Learning Objectives
• Define CKD
• Review screening guidelines for CKD
• Review staging of CKD
• Outline diagnostic approach
• Review primary care management
• Understand indications for referral to specialty care

We will NOT cover
• Diagnosis or management of AKI
• In-depth management of advanced/end-stage disease
• Management of patients with renal transplant
• Management of CKD in pediatric patients
• Pharmacologic adjustments in CKD
• IV contrast prophylaxis or management

Definition
• Abnormal kidney structure or function
• GFR <60 or urinary albumin >30 mg/day
• Must be present for >3 months

Chronic kidney disease is not a primary diagnosis

Role of the PCP

• Screening
• Slowing disease progression
• Preventing complications

Our Patient
WH is a 55-year-old male presenting to clinic for an initial
visit to establish care. He reports a past medical history of
type 2 diabetes, hyperlipidemia, coronary artery disease
s/p CABG, peripheral vascular disease s/p R BKA, and
peptic ulcer disease.
VS: BP 125/85 HR 88 T 98F O2 98%
PE: Normal exam with exception of right BKA with prosthesis

The Plan
WH brought his medication bottles with him. They include:
-

-

Aspirin 81 mg
Carvedilol BID
Dulaglutide
Rosuvastatin
Ramipril
Insulin
Metformin
Tamsulosin

He has not seen a PCP in some time. What labs or screening do
you want to order?

Who do we screen?
Universal screening is not recommended
“The U.S. Preventive Services Task Force found
insufficient evidence to assess the balance of benefits and
harms of screening for chronic kidney disease in the
general population, and the American College of
Physicians recommends against screening asymptomatic
adults without risk factors.”

Screening At-Risk Populations
Diabetes and hypertension are the leading causes
of kidney failure in the US, accounting for 75% of
new cases of CKD

Additional risk factors: age >60 yrs, family history of kidney
disease, cardiovascular disease, obesity

Screening Method
• Measure eGFR and proteinuria
• Urine Albumin/Creatinine ratio
• Creatinine alone is not sufficient
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Lab Results
Creatinine: 1.21
eGFR: 67
Albumin/Creatinine: 391 mg/g
Previous albumin/Cr: 354 mg/g 1 year ago

Initial Workup
• Thorough history and physical
• Exposure to nephrotoxins
• Blood pressure, diet, weight history
• Electrolytes
• Lipids, A1c

Other Causes of CKD
•
•
•
•
•

Medications
SLE
HIV
CHF
Hepatorenal syndrome

•
•
•
•
•

Nephrolithiasis
Benign prostatic hyperplasia
Glomerulonephritis
Multiple myeloma
Genetics

When to image
• Not routinely indicated
• Ultrasound when there is a history of urinary tract
stones or obstruction, frequent UTIs, or a family
history of polycystic kidney disease

Role of the PCP

• Screening

• Slowing disease progression
• Preventing complications

RAS Blockade
• ACE inhibitors are recommended treatment for
nondiabetic CKD over ARBs
• Use of an ACE inhibitor in CKD is associated with a
31% reduction in end stage renal disease

Our patient
• WH meets criteria for G2, A3 diabetic kidney disease
• He is already on an ACE inhibitor
• Hgb A1c is 9.2
• Blood pressure is well controlled
• Which other medication would he benefit from?

Treatment in Diabetic Kidney Disease
• ACE inhibitors + ARBs are equally beneficial at slowing
nephropathy in diabetic CKD
• Dual ACE inhibitors + ARBs are not beneficial and have
harmful effects
• Initiate SGLT2 inhibitor, especially in patients with
severe albuminuria

Frequency of monitoring
PROTEINURIA
• At risk populations: screen annually
• DKD: every 3-6 months
• CKD 3: twice yearly
• CKD 4: four times yearly

PCP Management
• Blood pressure: goal <130/80 (per ACC/AHA 2017
guideline)
• Blood glucose: A1c goal 7%
• Lifestyle: smoking cessation
• Diet: recommend <2000 mg sodium daily
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Aspirin & CKD
• Primary prevention: insufficient data to suggest
empiric use or avoidance of aspirin
• Ongoing clinical trial, Aspirin to Target Arterial Events
in Chronic Kidney Disease (ATTACK) looking at risk
reduction of MI and stroke in CKD with daily aspirin use

Our Patient’s Prognosis
• He is on an ACE inhibitor and an SGLT-2 inhibitor was
started
• Blood pressure is well controlled, weight is in a healthy
range
• What is his prognosis in the long term?

Prognosis

Role of the PCP

• Screening
• Slowing disease progression

• Preventing complications
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Screening Intervals for Complications of CKD
METABOLIC BONE DISEASE
• Stage 3: measure calcium, phosphorus, bicarbonate,
PTH, ALP, and vitamin D once as a baseline
• Stage 4: PTH, calcium, phosphorus every 3 months
• Stage 5: calcium and phosphorus monthly

Anemia
• Usually due to iron deficiency rather than
erythropoietin deficiency
• Measure Hgb annually in CKD stage 3

Bone Density
• Stage 1-3a CKD patients can be screened according to
general osteoporosis guidelines
• CKD is not a specific indication for osteoporosis
screening, not recommended to test routinely
• Not indicated to routinely prescribe vitamin D without
known vitamin deficiency

When to refer to Nephrology
•
•
•
•
•
•
•
•

GFR <30
Significant albuminuria
Rapid drop in GFR
Unexplained or persistent hematuria
Secondary hyperparathyroidism
HTN refractory to treatment with >4 agents
Recurrent nephrolithiasis
Unknown cause of CKD

Summary
• Screen at risk populations (DM + HTN)
• ACE, ACE baby
• Identify the cause and timeline of altered kidney function
• Minimize risk factors: statin, smoking cessation, blood
pressure, blood sugar
• Monitor for complications starting at CKD stage 3
• Don’t be afraid to refer to nephrology

Questions?

www.newyorker.com
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